Bharat Biotech, Biofabri in tech transfer deal for TB vaccine

MTBVAC, the TB vaccine, has undergone Phase I and II clinical trials in India. The vaccine has demonstrated safety and immunogenicity. Based on the initial results, Bharat Biotech is preparing for a pivotal Phase III vaccine efficacy study. It will start recruiting participants in the first quarter of 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eK3d1uL
via IFTTT